Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

@article{Pu2016AndrogenRA,
  title={Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse},
  author={Yang Pu and Meng Xu and Yong Liang and Kaiting Yang and Yajun Guo and Xuanming Yang and Yang-Xin Fu},
  journal={Science Translational Medicine},
  year={2016},
  volume={8},
  pages={333ra47-333ra47}
}
Surgical and medical androgen deprivation therapy (ADT) is a cornerstone for prostate cancer treatment, but relapse usually occurs. We herein show that orchiectomy synergizes with immunotherapy, whereas the more widely used treatment of medical ADT involving androgen receptor (AR) antagonists suppresses immunotherapy. Furthermore, we observed that the use of medical ADT could unexpectedly impair the adaptive immune responses through interference with initial T cell priming rather than in the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 14 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 4 Excerpts
Highly Influenced

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2008
View 4 Excerpts
Highly Influenced

Immunotherapy in prostate cancer: review of the current evidence.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2015
View 1 Excerpt

Combination therapy with a second - generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model

B. D. Car, H. Shi, +9 authors M. M. Gottardis
Clin . Cancer Res . • 2013

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…